Current Report No.
14/2023
Date of preparation: 2023-06-14
Abbreviated name of the issuer: MEDICALGORITHMICS S.A.
Subject: Admission and conditional introduction of the Company’s series
I shares to trading on the main market of the WSE. Setting the date of
the first listing of the Company’s series I shares after their
assimilation with shares traded on the main market.
Legal basis: Art. 56 (1) (2) of the Act on Offering – current and
periodic information.
Contents of the report:
The Management Board of MEDICALGORITHMICS S.A. with its seat in Warsaw
[Issuer, Company], hereby informs that on June 14, 2023 it received
information on the adoption of Resolution No. 562/2023 of the Management
Board of the Warsaw Stock Exchange on June 14, 2023 [WSE] regarding the
admission and introduction to trading on the WSE Main Market of series I
ordinary bearer shares of the Company [Resolution].
Pursuant to the Resolution, 995,276 [nine hundred and ninety-five
thousand two hundred and seventy-six] series I bearer common shares of
the Company carrying ISIN code PLMDCLG00031 [Shares], with a nominal
value of 0.10 [ten grosz] each, were admitted to trading on the main
market.
Pursuant to the Resolution, the Shares will be listed on the main market
as of June 21, 2023, subject to the assimilation of the Shares by the
National Securities Depository S.A. [Krajowy Depozyt Papierów
Wartościowych SA] on June 21, 2023 with the Company’s shares traded on
the stock exchange, under the code PLMDCLG00015. The Company will
announce the assimilation of the Shares in a separate current report.
The Company reminds that the Shares were issued in accordance with the
Resolution No. 4 of the Company’s Extraordinary General Meeting of
October 28, 2022 Increase of the Company’s share capital through issue
of series I, J, K and L shares; waiver of existing shareholders’
subscription rights; private subscription offer for a designated entity;
and change of Article 5 (1) and (2) of the Articles of Association. The
shares were registered with the National Securities Depository on March
7, 2023, as the Company announced in current report number 8/2023 on
March 8, 2023.
The Company reminds
that in the current report No. 55/2022 it informed on October 1, 2022
that 4,976,384 Shares were acquired by Biofund Capital Management LLC
with its registered office in Miami (USA). These shares are to be
introduced to trading under the applicable exceptions to the obligation
to prepare an issue prospectus, and the planned date of introducing all
these shares to trading has been set at the end of 2026.
Zgłoś naruszenie/Błąd
Pozytywnie
Neutralnie 
Negatywnie
Lubię to!
Super
Ekscytujący 
Ciekawy
Smieszny
Smutny
Wściekły
Przerażony
Szokujący
Wzruszający
Rozczarowany
Zaskoczony
Prawda
Manipulacja
Fake news
Oryginalne źródło ZOBACZ
Dodaj kanał RSS
Musisz być zalogowanym aby zaproponować nowy kanal RSS